Corporate ActionMay 5, 2026, 04:17 PM
Cytokinetics to Offer $650M in Common Stock Public Offering
AI Summary
Cytokinetics, Incorporated announced plans for an underwritten public offering of approximately $650 million of its common stock. The company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares sold in connection with the offering. Morgan Stanley, Goldman Sachs & Co. LLC, J.P. Morgan, and Jefferies are acting as joint book-running managers for the offering.
Key Highlights
- Cytokinetics plans to offer approximately $650 million of shares of its common stock.
- The offering will be an underwritten public offering.
- Underwriters will receive a 30-day option to purchase up to an additional 15% of shares.
- All shares in the offering will be sold by Cytokinetics.
- Morgan Stanley, Goldman Sachs & Co. LLC, J.P. Morgan, and Jefferies are joint book-running managers.